Impact Capital Partners LLC Purchases Shares of 8,064 The Cooper Companies, Inc. (NASDAQ:COO)

Impact Capital Partners LLC purchased a new position in shares of The Cooper Companies, Inc. (NASDAQ:COO) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 8,064 shares of the medical device company’s stock, valued at approximately $741,000.

Other institutional investors also recently made changes to their positions in the company. Principal Financial Group Inc. boosted its position in Cooper Companies by 6.6% during the third quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock valued at $26,295,000 after acquiring an additional 14,687 shares during the last quarter. Covestor Ltd raised its holdings in shares of Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after acquiring an additional 200 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Cooper Companies in the 3rd quarter worth about $25,000. Venturi Wealth Management LLC increased its stake in Cooper Companies by 40.4% in the 3rd quarter. Venturi Wealth Management LLC now owns 4,699 shares of the medical device company’s stock valued at $518,000 after buying an additional 1,351 shares during the last quarter. Finally, GSA Capital Partners LLP increased its stake in Cooper Companies by 150.6% in the 3rd quarter. GSA Capital Partners LLP now owns 6,993 shares of the medical device company’s stock valued at $772,000 after buying an additional 4,202 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. JPMorgan Chase & Co. cut their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Morgan Stanley decreased their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Wells Fargo & Company lifted their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Robert W. Baird dropped their price objective on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th. Finally, StockNews.com downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $111.89.

Cooper Companies Stock Performance

COO opened at $79.07 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The firm has a fifty day moving average price of $91.67 and a 200 day moving average price of $99.11. The stock has a market cap of $15.78 billion, a P/E ratio of 40.55, a P/E/G ratio of 2.25 and a beta of 1.02. The Cooper Companies, Inc. has a 1 year low of $78.43 and a 1 year high of $112.38.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. The firm had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.